3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Leiomyosarcoma
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Surgical Procedures, Operative
14
Magnetic Resonance Spectroscopy
14
Gemcitabine
13
Blood Specimen Collection
13
Biopsy
13
Radiotherapy
12
fludarabine
11
atezolizumab
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
6
selinexor
5
liposomal doxorubicin
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Midazolam
×
Sarcoma
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled